- FXR receptor agonist
-
The present invention discloses an FXR receptor agonist, belongs to the technical field of medicine, and particularly relates to a compound represented by a formula (I), a pharmaceutically acceptablesalt, an ester or a stereoisomer thereof, wherein R, R, R, M, L, L1, W, A , B, Q, m and n are defined in the specification. The present invention further relates to a preparation method of the compound, a pharmaceutical preparation, and applications in preparation of drugs for treatment and/or prevention of nonalcoholic fatty liver disease, primary biliary cirrhosis, lipid metabolism disorder, diabetic complication, malignant tumors and other related diseases mediated by FXR receptors. The formula I is defined in the specification.
- -
-
-
- Imidazo[1,2-a]pyridine derivatives, methods of preparing the same and use thereof
-
The present invention relates to an imidazo[1,2-a]pyridine derivative, and more specifically, to an imidazo[1,2-a]pyridine derivative having excellent gastric acid secretion inhibitory activity, a method of preparing the same, and a use thereof. The imidazo[1,2-a]pyridine derivative according to the present invention has gastric acid secretion inhibitory activity, and can be usefully applied for preventing or treating gastrointestinal inflammatory diseases or gastric-related diseases.(AA) Control group(BB) Example 6(CC) Example 7(DD) Embodiment 11COPYRIGHT KIPO 2017
- -
-
-
- 2-BENZYL-BENZIMIDAZOLE COMPLEMENT FACTOR B INHIBITORS AND USES THEREOF
-
The present invention provides a compound of formula (I) a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical comp
- -
-
Page/Page column 48
(2015/05/19)
-
- N-PYRAZOLYL CARBOXAMIDES AS CRAC CHANNEL INHIBITORS
-
The present invention relates to amide compounds, processes for their preparation, pharmaceutical compositions containing these compounds and to their use in the treatment of disorders, conditions or disorders such as allergic disorders, inflammatory disorders and disorders of the immune system.
- -
-
Page/Page column 75-76
(2010/11/05)
-
- Regioselective reductive opening of substituted phthalans: synthetic applications
-
The reductive opening of substituted phthalans 6, 11, 12, 20, 21 and 28 with lithium and a catalytic amount of DTBB leads to the formation of corresponding functionalised organolithium intermediates 8, 15, 16, 23, 25 and 29+30 in a regioselective manner. The further reaction of these dianions with different electrophiles, mainly carbonyl compounds, gives the expected functionalised benzylic alcohols 9, 17, 18, 24, 26 and 31+32. The observed stereochemistry can be easily explained taking into account the values of the electron densities deduced by semiempirical PM3 calculations.
- García, Daniel,Foubelo, Francisco,Yus, Miguel
-
p. 4275 - 4286
(2008/09/20)
-
- Phytochemical study on American plants I. Two new phenol glucosides, together with known biflavones and diterpene, from leaves of Juniperus occidentalis Hook.
-
Two new phenol glucosides termed juniperosides I (1) and II (2) were isolated, together with known two biflavones, cupressuflavone and amentoflavone and a diterpene, 3beta-hydroxy sandaracopimaric acid, from leaves of Juniperus occidentalis HOOK. (Cupress
- Nakanishi, Tsutomu,Inatomi, Yuka,Murata, Hiroko,Iida, Naoki,Inada, Akira,Lang, Frank A,Murata, Jin
-
p. 1358 - 1361
(2007/10/03)
-
- A facile synthesis of [14C]enadoline [(5R)-(5α,7α,8β)]-N-methyl-N-[7-(1-pyrrolidinyl)-1-oxospiro[4,5] dec-8-yl]-4-benzofuranacetamide
-
4-Chloromethylbenzofuran (10) was synthesized from 2,3-dimethylanisole in 7 steps. The corresponding Grignard reagent prepared from magnesium anthracene complex reacts with 14CO2, SOCl2, and PD130812 successively to give [
- Pu,Scripko,Huang
-
p. 1183 - 1191
(2007/10/03)
-